12:00 AM
Jun 23, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Integrin avβ3 (CD51/CD61)



In vitro and mouse studies identified a protein inhibitor of the integrin CD51/CD61 that could help treat cancer. In silico analysis of the binding interaction of CD2 analogs with CD51/CD61 and in vitro binding assays of the analogs identified a protein that bound CD51/CD61 outside the known CD2 binding site with...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >